复方阿嗪米特联合莫沙必利治疗老年消化不良患者的临床效果

Clinical effect of compound azintamide combined with mosapride in the treatment of elderly patients with dyspepsia

目的 研究复方阿嗪米特联合莫沙必利治疗老年消化不良患者的临床效果.方法 选取我院2017年10月至2018年9月收治的110例老年消化不良患者作为研究对象,按照随机数字表法将其分为对照组(55例)与观察组(55例),在常规治疗的基础上,对照组采用莫沙必利进行治疗,观察组采用复方阿嗪米特联合莫沙必利进行治疗.比较两组的临床症状积分、临床症状改善时间、消化不良发作频率、临床效果及不良反应发生情况.结果 治疗后,两组患者的恶心呕吐、食欲不振、腹痛腹胀、反酸嗳气积分均降低,且观察组显著低于对照组,差异具有统计学意义(P<0.05).观察组的恶心呕吐、食欲不振、腹痛腹胀、反酸嗳气改善时间均显著短于对照组,差异具有统计学意义(P<0.05).治疗后,两组患者消化不良的发作频率均降低,且观察组显著低于对照组,差异具有统计学意义(P<0.05).观察组的临床治疗总有效率为98.18%,显著高于对照组的81.82%,差异具有统计学意义(P<0.05).观察组的不良反应总发生率为5.45%,显著低于对照组的20.00%,差异具有统计学意义(P<0.05).结论 复方阿嗪米特联合莫沙必利治疗老年消化不良患者安全、有效,能够减轻患者的临床症状严重程度并减少发作频率,加快临床症状改善速度.

Objective To study the clinical effect of compound azintamide combined with mosapride in the treatment of elderly patients with dyspepsia. Methods A total of 110 elderly patients with dyspepsia admitted in our hospital from October 2017 to September 2018 were selected as the study objects. According to the random number table method, the patients were divided into control group(55 cases) and observation group(55 cases). On the basis of conventional treatment, the control group was treated with mosapride, while the observation group was treated with compound azintamide combined with mosapride. The clinical symptom scores, the improvement time of clinical symptom, frequency of dyspepsia, clinical effects and adverse reactions were compared between the two groups. Results After treatment, the scores of nausea and vomiting,loss of appetite, abdominal pain and abdominal distension, acid regurgitation and belching in both groups decreased, and those in the observation group were significantly lower than the control group, the differences were statistically significant(P<0.05). The times of nausea and vomiting, loss of appetite, abdominal pain and abdominal distension, acid regurgitation and belching in the observation group were significantly shorter than those in the control group, the differences were statistically significant(P<0.05). After treatment, the frequency of dyspepsia in both groups decreased, and that in the observation group was significantly lower than the control group, the differences were statistically significant(P<0.05). The total effective rate of clinical treatment in the observation group was 98.18%, which was significantly higher than 81.82% in the control group, the difference was statistically significant(P<0.05). The total incidence of adverse reactions in the observation group was 5.45%,which was significantly lower than 20.00% in the control group(P<0.05). Conclusion Compound azintamide combined with mosapride in the treatment of elderly patients with dyspepsia is safe and effective. It can reduce the severity of clinical symptoms and attack frequency, and accelerate the improvement of clinical symptoms.